Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Plasma cell 1Genitourinary 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × L-BLP25 × Thoracic × Clear all
NCT00828009 2023-07-07

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Eastern Cooperative Oncology Group

Phase 2 Completed
70 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00157209 2015-11-18

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
171 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00157196 2015-08-18

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
22 enrolled 6 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡